EVGN250221P7500
- 0.00
- 0.000.00%
Evogene Newsroom
Evogene's Lavie Bio Retains Tech Amid Corteva Exit
Express News | Evogene Ltd: Unit Receives Notice of Termination of Licensing Agreement With Corteva for Bio Fungicide Lead Candidates
Lake Street Maintains Evogene(EVGN.US) With Buy Rating, Cuts Target Price to $5
Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript Summary
Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript
Evogene Sees Revenue Growth and Expands AI Collaboration
Earnings Flash (EVGN) EVOGENE Reports Q3 Revenue $1.8M, Vs. Street Est of $2.9M
Evogene | 6-K: Report of foreign private issuer (related to financial reporting)
Evogene GAAP EPS of -$1.31 Misses by $0.30, Revenue of $1.8M Misses by $1.05M
Evogene Q3 2024 GAAP EPS $(1.31) Misses $(0.63) Estimate, Sales $1.80M Miss $2.85M Estimate
Evogene Sees 2024 Continued Rev Growth Comparable to 2023 >EVGN
Evogene 3Q Loss/Shr $1.31 >EVGN
Earnings Scheduled For November 21, 2024
Here's the Major Earnings Before the Open Tomorrow
A Glimpse of Evogene's Earnings Potential
Lavie Bio Advances Its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results
Earnings Preview: Evogene to Report Financial Results Pre-market on November 21
$Evogene(EVGN.US)$ is scheduled to release its financial results pre-market on November 21 ET. Earnings PreviewAnalysts estimate $Evogene(EVGN.US)$ to post revenue of USD2.85M for 2024Q3, down 24.34%
Lavie Bio Announces Commercial Expansion of Yalos as Seed-Treatment for Soybean, Following Successful Field Trials
Evogene Schedules Third Quarter 2024 Financial Results Release
Evogene, Google Collaborate to Build AI Model for Small Molecule Design